Posted by Michael Wonder on 11 Sep 2017
Institute for Clinical and Economic Review posts updated economic analyses for PCSK9 inhibitor evolocumab, finds less favourable cost-effectiveness
11 September 2017 - To reflect new clinical trial evidence, updated ICER value-based price benchmark for a year of treatment with evolocumab lowered to range between $1,725 and $2,242.
Following the March 2017 release of clinical evidence on evolocumab (Repatha, Amgen) from the FOURIER trial, the ICER has used those data to update its analysis of the drug’s long-term cost-effectiveness, and has posted these results along with an updated value-based price benchmark as the final component of ICER’s New Evidence Update on evolocumab.
Replacing earlier assumptions about treatment outcomes with actual clinical results, the updated analyses find evolocumab to be less cost-effective, leading to a lower calculated range for a value-based price that would align with the added benefit for patients.
